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In this issue, Toubiana and colleagues 1 offer the fullest picture to date of the 
complex primary immunodeficiency caused by heterozygous gain-of-function 
(GOF) mutations of STAT1 (Signal Transducer and Activator of Transcription 1).  
It is five years since such mutations were first shown to cause an intriguing 
familial susceptibility to severe superficial fungal infection alongside 
autoimmune disease, often in the form of hypothyroidism 2 3.  Since then, clinical 
immunologists have come to recognize STAT1-GOF as the major genetic etiology 
for chronic mucocutaneous candidiasis disease (CMCD).  The present 
international case series 1 highlights the broader immunodeficiency phenotype 
that accompanies CMC in such patients, contributing to severe morbidity and 
very significant early mortality.  Inborn errors such as STAT1-GOF thus offer 
both a window onto the human immune system and a grand challenge to 
advocates of precision medicine. 
 
STAT1 encodes one of the STAT family of transcription factors that are activated 
by Janus kinases (JAKs) downstream of cytokine and interferon receptors4.  JAKs 
and STATs thus underpin contact-independent cell signaling throughout the 
immune system.  The phosphorylated STATs translocate to the nucleus, form 
complexes with each other and with DNA to influence gene transcription, until 
they are deactivated by dephosphorylation.  Different STATs talk to different 
receptors and genes but eavesdrop on each others’ conversations.  Too much 
STAT1 seems to drown out the STAT3 signal that is required to drive T cells 
towards the interleukin-17-producing, candida-resisting Thelper17 (Th17) cell 
fate 3.  Since IL17 is so important for antifungal immunity at epithelial surfaces, 
CMC results.  A reciprocal defect in the form of STAT3 loss-of-function (LOF) also 
predisposes to CMC but not to autoimmunity – this disorder is better known for 
the unpleasant staphylococcal infections of lung and skin that earn it the epithet 
“Job’s syndrome” 4.   
 
Toubiana et al. have now coordinated an outstanding international effort to 
document the extended clinical phenotype of STAT1-GOF 1 (summarized in 
figure 1).  Biochemical confirmation that documented missense mutations were 
biochemically GOF was obtained in every case. By searching for and including 
family members who shared the STAT1 genotype of individuals presenting with 
CMCD, they show that this disorder is fully penetrant with a median age of onset 
of only 12 months.  The vast majority (98%) of individuals suffered chronic 
mucocutaneous candidiasis that frequently (75%) required longterm antifungal 
therapy and often (~30%) went on to develop resistance – leading to years of 
discomfort and complications including difficulty swallowing and cancerous 
change, especially of the esophagus.   
 
That STAT1-GOF causes CMC is not new, but among the most striking results of 
this study are the very high rates of bacterial and viral infection afflicting these 
patients, as well as invasive fungal infection and nontuberculous mycobacterial 
disease.  Sinopulmonary infections were extremely common and led to structural 
lung damage in around a fifth of patients.  Mucocutaneous involvement was not 
confined to mycosis but included bacterial skin infections in more than one 
fourth of patients and atypical viral disease in one third (especially zoster, 
Herpes simplex; also warts and Molluscum).   
 
Among non-infective complications, aneurysm was documented in 6%, mostly 
cerebral; as in patients with STAT3-LOF, this constitutes a significant mortality 
risk and Toubiana et al. recommend systematic radiological screening.  
Autoimmune phenomena covered a wide range, from type I diabetes to 
scleroderma, and many more patients showed autoantibody production.  
Immunological hallmarks suggested by earlier studies were not universal, 
although many of those tested had low Th17 cell numbers and around half had 
reduced memory B cells.  Patients with low B cell or CD4 cell numbers were at 
greater risk of invasive infection. 
 
Given the extent and severity of complications, it is not surprising that survival 
was significantly impaired.  Deaths were predominantly due to invasive 
infection, cancer and cerebral hemorrhage secondary to aneurysm. These 
occurred across the life course, at a median age of 30.  Although not measured in 
this study, we can expect that quality of life was significantly impaired in the 
majority of patients who remained symptomatic from their CMC and/or 
bronchiectasis.   This represents a substantial burden of morbidity and mortality 
for a childhood onset primary immunodeficiency. 
 
These findings emphasize that STAT1-GOF is not a pathogen-specific disorder 
but instead should be considered a combined immunodeficiency.  In keeping 
with this concept, there is already clear evidence that STAT1-GOF impacts not 
only Th17 generation 3 but also T follicular helper cell phenotype and 
effectiveness and B cell memory 5 6.  Since cytokines and interferons provide 
critical contextual cues that influence lymphocyte polarization and behavior, this 
is perhaps not surprising.   
 
Doubtless we have more to learn about the subtleties of JAK-STAT biology within 
the immune system but can we use existing knowledge for patient benefit?  
Targeted therapy is the holy grail that would allow us to treat inborn errors 
pharmacologically with minimal side effects.  Arising from the understanding 
that STAT1 signaling remains JAK-dependent, two groups have recently reported 
use of the JAK inhibitor Ruxolitinib in STAT1-GOF, with positive benefit in both 
(although much more marked in one patient 7 than the other 8).  Administration 
of granulocyte colony stimulating factor, a plausible means to boost STAT3 
signaling that appeared miraculously effective in one patient 9, produced no 
benefit in another 10.  We are therefore only at the beginning of the long road to 
precision medicine for STAT1-GOF, and the generation of a faithful knock-in 
mouse model may be a crucial stepping stone to future clinical trials.  Meanwhile, 
the curative potential of hematopoietic stem cell transplant for STAT1-GOF is 
beginning to be explored and an international survey of experience to date is 
currently being compiled.   
 
Figure legends 
 
Figure 1 
Infective and non-infective complications of gain-of-function mutations in 
STAT1.  Data derived from Toubiana et al 1. Professional illustration by Alison 
Schroeer, Schroeer Scientific Illustration. 
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